Melanocortin receptor ligands

Patent metadata

Field	Value
Publication number	US-9850280-B2
Application number	US-201715587426-A
Country	US
Kind code	B2
Filing date	May 5, 2017
Priority date	Jul 8, 2005
Publication date	Dec 26, 2017
Grant date	Dec 26, 2017

Abstract

The present invention is directed to compounds according to formula,

(R 2 R 3 )-A 1 - c (A 2 -A 3 -A 4 -A 5 -A 6 -A 7 -A 8 -A 9 )-A 10 -R 1 ,

and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.

First claim

What is claimed is:

1. A compound selected from the group consisting of:
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH 2 (SEQ ID NO:24);
D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-NH 2 (SEQ ID NO:3);
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH 2 (SEQ ID NO:3);
D-Phe-c(Cys-His-D-Phe-hArg-Trp-β-Ala-D-Cys)-Thr-NH 2 (SEQ ID NO:23);
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH 2 (SEQ ID NO:24);
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-NH 2 (SEQ ID NO:26);
D-Phe-c(Cys-His-D-Phe-Arg-Bip-β-Ala-D-Cys)-Thr-NH 2 (SEQ ID NO:25);
D-Phe-c(Cys-His-D-Phe-hArg-Bip-β-Ala-D-Cys)-Thr-NH 2 (SEQ ID NO:26); and
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH 2 (SEQ ID NO:11);
or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 , wherein the compound is D-Phe-c(Cys-His-D-Phe-Arg-Bip-β-Ala-D-Cys)-Thr-NH 2 (SEQ ID NO:25) or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 1 , wherein the compound is D-Phe-c(Cys-His-D-Phe-hArg-Bip-β-Ala-D-Cys)-Thr-NH 2 (SEQ ID NO: 26) or a pharmaceutically acceptable salt thereof.

4. A compound according to claim 1 , wherein the compound is D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-NH 2 (SEQ ID NO:26) or a pharmaceutically acceptable salt thereof.

5. A compound according to claim 1 , wherein the compound is D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH 2 (SEQ ID NO:24) or a pharmaceutically acceptable salt thereof.

6. A compound according to claim 1 , wherein the compound is Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH 2 ; (SEQ ID NO:11) or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

8. A method of treating a metabolic disease or medical condition accompanied by weight gain, comprising administering to a subject in need thereof a therapeutically effective amount of compound of claim 1 .

9. The method of claim 8 , wherein the disease or condition is selected from obesity, feeding disorders, Prader-Willi Syndrome, or diabetes.

Assignees

• Ipsen Pharma Sas

Inventors

• Dong Zheng Xin
• Moreau Jacques-Pierre

Classifications

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P3/08

  for glucose homeostasis (pancreatic hormones A61P5/48) · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title